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Abstract
Rationale: In asthma, goblet cell numbers are increased within the airway epithelium, 
perpetuating the production of mucus that is more difficult to clear and results in airway mucus 
plugging. Notch1, 2 or 3, or a combination of these have been shown to influence differentiation 
of airway epithelial cells. How the expression of specific Notch isoforms differs in fully 
differentiated adult asthmatic epithelium and whether Notch influences mucin production 
following differentiation is currently unknown.
Objectives: We aimed to quantify different Notch isoforms in the airway epithelium of severe 
asthmatics and to examine the impact of Notch signaling on mucin MUC5AC. Human lung 
sections and primary bronchial epithelial cells from asthmatics and non-asthmatics were used in 
this study.
Methods: Primary bronchial epithelial cells were differentiated at air-liquid interface for 28 days. 
Notch isoform expression was analyzed by Taqman qPCR. Immunohistochemistry was used to 
localize and quantify Notch isoforms in human airway sections. Notch signaling was inhibited in 
vitro using dibenzazepine or Notch3-specific small interfering RNA, followed by analysis of 
MUC5AC. 
Measurements and Main Results: NOTCH3 was highly expressed in asthmatic airway 
epithelium compared to non-asthmatic. Dibenzazepine significantly reduced MUC5AC 
production in air-liquid interface cultures of primary bronchial epithelial cells, concomitant with a 
suppression of NOTCH3 intracellular domain protein. Specific knockdown using NOTCH3 
siRNA recapitulated the dibenzazepine-induced reduction in MUC5AC.
Page 3 of 47
 AJRCMB Articles in Press. Published January 10, 2020 as 10.1165/rcmb.2019-0069OC 
 Copyright © 2020 by the American Thoracic Society 
Conclusions: We demonstrate that NOTCH3 is a regulator of MUC5AC production. Increased 
NOTCH3 signaling in the asthmatic airway epithelium may therefore be an underlying driver of 
excess MUC5AC production.
Word Count: 246 words
Keywords: Notch Signaling, Airway Epithelium, Mucus, MUC5AC, Pharmacological Inhibition.
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Mucus overproduction is one of many irregularities typically associated with inflammatory airway 
diseases asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. When 
coupled with increases in viscosity, it is linked to defective mucociliary clearance and the 
formation of mucus plugs that cause airflow obstruction (1, 2). Two major gel-forming mucins 
exist in the airway mucus layer, MUC5AC and MUC5B. There is now strong evidence that 
submucosal glands and distal airways are the predominant sites of MUC5B expression, whilst 
proximal and cartilaginous airway epithelia are sites of both MUC5AC and MUC5B expression in 
the normal human lung (3, 4). Production of MUC5AC increases in patients with asthma (5), 
whereas MUC5B production varies. Levels of MUC5AC directly correlate with mucus 
viscoelasticity and airway mucus accumulation indicating that MUC5AC over-production is a 
driver of disease in asthma (6).
The NOTCH family of proteins, Notch1-4, are single-pass membrane receptor proteins responsible 
for regulating cell proliferation, differentiation and cell death (7). Numerous studies have 
demonstrated that NOTCH signaling controls goblet cell differentiation within the airway 
epithelium both in humans and mice (8-11). Notch signaling is activated via ligand-induced 
cleavage events, the final of which is facilitated by gamma-secretase leading to the nuclear 
translocation of the Notch intracellular domain (NICD) and subsequent gene expression (12). 
Signaling through the Notch1, 2 and 3 isoforms can determine whether airway epithelial cells 
differentiate to become goblet cells or ciliated cells (10, 13, 14). Pharmacological inhibition of 
Notch signaling prevents airway basal cells from differentiating into goblet cells (10, 13). To date 
very few studies have investigated Notch isoform expression and signaling in the fully 
differentiated airway epithelium and the impact, if any, of asthma on these parameters. 
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We hypothesized that Notch signaling is dysregulated in differentiated airway epithelial cells from 
asthmatics driving excess MUC5AC production. To investigate this we used air-liquid interface 
(ALI) cultures of primary bronchial epithelial cells (pBECs) from asthmatics and non-asthmatics 
(15). We show that the airway epithelium of asthmatics exhibits increased NOTCH3 and decreased 
NOTCH1 expression. Furthermore, inhibition of the NOTCH3 intracellular domain (NICD3) 
reduces mucin production in epithelial cell cultures from asthmatics and non-asthmatics grown at 
ALI. Notch3 appears to be a regulator of mucin production within the airway epithelium and its 
expression and activity is increased in asthma. Future studies targeting Notch3 may reveal its 
viability as a target to treat airways diseases where mucus hypersecretion is a pathological feature. 
Methods
Study approvals
All experiments were conducted in accordance with Hunter New England Area Health Service 
Ethics Committee and University of Newcastle Safety Committee (85/2012) approvals.
pBEC collection
pBECs were obtained from individuals clinically assessed as asthmatic (n=11) or non-asthmatic, 
all of whom were non-smokers (n=11) (Table 1). Asthmatics had a documented history of 
bronchial hyperresponsiveness and were defined as severe asthmatic according to GINA 
guidelines. Individuals underwent fiber-optic bronchoscopy as previously described (16). Briefly, 
brushings were made from 3rd generation bronchi and airway epithelial cells were isolated, 
cultured and passaged as previously described (17). Minimally-immortalized bronchial epithelial 
cells (BCi-Ns1.1) were donated by Prof. RG Crystal (18).
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pBEC cell culture and pharmacological inhibition
Cells were maintained in bronchial epithelial cell growth medium (BEGM; Lonza) as previously 
described (17). Cells were maintained at ALI for 25 days prior to pharmacological treatment with 
dibenzazepine (DBZ) (YO-01027; Selleck Chemicals, TX, USA) (online supplement). DBZ which 
is a highly selective gamma-secretase inhibitor was used at concentrations up to 10μM based on 
Notch inhibition studies in breast cancer cells (19). Cells were harvested for RNA, protein or fixed 
in 10% Formalin (Lomb Scientific, NSW, Australia) for histology.
BCI-Ns1.1 cell culture and siRNA transfection
BCI-Ns1.1 cells, derived from primary bronchial epithelial cells were used for siRNA transfections 
experiments due their documented ease of transfection (20). Furthermore, these cells recapitulate 
the cell responses witnessed in our primary cell cohorts. BCi-NS1.1 cells were maintained in 
BEGM containing penicillin-streptomycin (100U/mL-100µg/mL final) and Amphotericin 
(2.5µg/mL final) until confluent. Cells were transfected as per manufacturer’s instructions using 
Notch3 siRNA (s9640; Thermo Fisher Scientific, MA, USA), Silencer Select negative control 
siRNA (4390843; Thermo Fisher Scientific), or media control (online supplement). 0.4ng/mL or 
25ng/mL recombinant human epidermal growth factor (rhEGF) (Lonza) were supplemented in 
media for standard culture and mucus generating culture respectively.
Human lung tissue immunohistochemistry and colorimetry
Human lung sections from 6 asthmatics and 6 non-asthmatics (University of British Columbia, 
BC, Canada), were subjected to immunohistochemical staining (IHC) (online supplement). A 
minimum of 4-5 airways were analyzed for each of the 12 donors. A maximum of 5 images were 
taken randomly per individual airway for analysis and were subjected to color deconvolution as 
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previously described (21) (online supplement). Each data point represents mean staining intensity 
of each airway analyzed.
Air-liquid interface protein extraction and immunoblotting
ALI cell protein was extracted in ice-cold lysis buffer and subjected to immunoblotting as 
previously described (21). Membranes were blocked and incubated with primary antibodies; anti-
NOTCH3 (0.2μg/mL), anti-NOTCH1 (0.2μg/mL), or anti-βactin (ab8227; Abcam) (0.05μg/mL) 
(online supplement). Densitometry reported as ratio of band of interest to respective ACTB and 
normalized to Non-asthmatic control via ImageLab 6.0.1 software (Bio-Rad, CA, USA).
IHC, immunofluorescence and Alcian blue/PAS staining in ALI cultures
ALI membranes were stained with alcian blue and periodic acid Schiff (PAS) or IHC using anti-
MUC5AC (2μg/mL; ab3649). For immunofluorescence (IF), ALI sections were labelled with anti-
NOTCH1 or anti-NOTCH3 in combination with anti-MUC5AC. Fluorescent secondary 
antibodies; donkey anti-rabbit alexafluor-488 (A-21207; Invitrogen, CA, USA) and donkey anti-
mouse alexafluor-594 (A-21203; Invitrogen) were used to visualize Notch and MUC5AC proteins 
respectively.  Semi-quantitative assessment of positively stained alcian blue/PAS overlap or DAB 
labeled MUC5AC area was made via color deconvolution (online supplement).
Real-time quantitative RT-qPCR
Quantitative PCR (qPCR) targeting NOTCH1 (Hs01062014_m1), NOTCH2 (Hs01050702_m1), 
NOTCH3 (Hs01128537_m1), NOTCH4 (Hs00965889_m1), SPDEF (Hs00171942_m1), HES2 
(Hs01021800_g1) and MUC5AC (Hs00873651_m1) was normalized to 18S ribosomal RNA (18S 
rRNA) (4318839; Thermo Fisher Scientific) as previously described (22). All qPCR results are 
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presented as log2 fold change relative to control with statistics performed on ΔΔCt from 
independent biological replicates (23) (online supplement).
MUC5AC ELISA
MUC5AC-rich protein was obtained from cultures of Calu-3 human lung adenocarcinoma 
epithelial cells grown to ALI (24). Serial dilutions were made of Calu-3 apical surface fluid and 
linear MUC5AC standard curve was confirmed (data not shown). Indirect ELISA was performed 
as previously described targeting MUC5AC (25) (online supplement).
Immunofluorescence and in-cell ELISA
For IF, cells were washed and incubated overnight with anti-MUC5AC (2μg/mL) followed by 
Alexa-fluor 594-conjugated donkey anti-mouse secondary antibody. Cells were counterstained 
with Hoechst 33342 (Sigma-Aldrich) (0.6μg/mL). For in-cell ELISA, blocked cells were incubated 
with biotinylated anti-MUC5AC, streptavidin and TMB as above.
Statistics
Non-parametric Mann-Whitney U test (two-tailed, unpaired, exact method) (GraphPad PRISM 
software, CA, USA) was used to determine statistical significance between two groups. For 
multiple comparisons, Kruskal-Wallis method was utilized. Individual P values are given, 
statistical significance was determined as P < 0.05.
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Results
NOTCH3 expression is increased in Asthma
pBEC cultures, from 11 severe asthmatic and 11 non-asthmatic donors (Table 1 for demographics), 
were differentiated at ALI for 29 days. Both non-asthmatic and asthmatic pBECs expressed 
baseline levels of NOTCH1-3 but not NOTCH4 mRNA (figure 1A).  NOTCH3 was elevated in 
ALI cultures from asthmatics (P = 0.003) compared to non-asthmatics. In contrast, NOTCH1 and 
NOTCH2 expression levels did not differ between both cohorts. NICD3, the cleaved/active Notch3 
protein, was higher 1.6 fold (P = 0.032) in pBEC ALIs from the asthma group compared to non-
asthmatic. Conversely, asthmatic NICD1 was significantly lower (0.3 fold; P = 0.008) compared 
to non-asthmatic (Figure 1B,C). NICD2 was difficult to detect within pBEC ALIs but showed no 
obvious difference between groups (Supplementary Figure E1). Based on these data we 
investigated Notch3 and Notch1 in human airways using IHC (Figure 1D). NOTCH3 was highly 
expressed in the airway epithelium of asthmatics, localizing to nuclei and the cell periphery.  In 
agreement with pBEC data, colour segmentation analysis demonstrated a greater (P = 0.004) level 
of NOTCH3 protein in the epithelium of asthmatic airways (Figure 1E). NOTCH1, which 
exhibited diffuse localization throughout the cytoplasm in the epithelium of non-asthmatics, was 
expressed at a significantly lower level (P < 0.0001) in asthmatic airways. 
Proximal localization of NOTCH1 and NOTCH3 with MUC5AC in ALI pBECs
NOTCH3 and NOTCH1 were analyzed for colocalization with MUC5AC using 
immunofluorescence (Figure 2). In pBEC ALIs from non-asthmatic donors NOTCH1 is strongly 
expressed and appears to localize in numerous columnar epithelial cells, often adjacent to 
MUC5AC producing goblet cells, potentially colocalizing with MUC5AC at the apical boundary 
of goblet and ciliated cells. NOTCH3 in these cells appears reduced in expression and evenly 
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distributed across most of the epithelial layer, potentially appearing more intense around areas of 
MUC5AC containing goblet cells. NOTCH1 detection is lower in pBECs from asthma donors 
compared to non‐asthma and does not localize solely to MUC5AC rich areas. Finally NOTCH3 
appears much more intense in pBEC ALIs from asthma donors, present both adjacent to and within 
the same cells as MUC5AC, although does not show direct colocalization.
DBZ treatment reduces NOTCH3 activation in addition to mRNA and protein expression in 
differentiated pBECs from asthmatics and non-asthmatics
Inhibition of Notch signaling was first confirmed in ALI pBECs following DBZ. In cells from 
non-asthmatics, NOTCH1 and 2 showed the same pattern of expression in which the lowest 
concentration of DBZ (0.1µM) showed a trending reduction of each isoform by ~40% its baseline 
value (P = 0.056 and 0,074 respectively) and higher concentrations of DBZ showed no appreciable 
difference to DMSO control (Figure 3A). In contrast, DBZ reduced NOTCH3 expression by ~85% 
in ALI cultures from both asthmatics and non-asthmatics at 0.1, 1 and 10μM (P = 0.049, 0.008 
and 0.026 respectively). Immunoblotting confirmed the equivalent reduction in NICD3 protein in 
both non-asthmatic and asthmatic cells (Figure 3B); however, no concentration-dependent 
reduction in NICD3 was observed. In contrast, NICD1 protein levels did not differ from baseline 
for any concentration of DBZ in either cohort. To confirm reduction in Notch3 signaling activity 
we quantified HES2 mRNA, a specific downstream target of Notch3 signaling when stimulated by 
the Y-box 1 binding protein (YB-1) ligand (26). HES2 similar to NOTCH3 is significantly elevated 
(P = 0.016) in pBECs from asthma donors (Figure 3C). Treatment with DBZ significantly inhibited 
expression of HES2 in pBECs from both cohorts. PBECs from non-asthma donors showed a 
concentration-dependent reduction in HES2 as opposed to the asthma group.
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DBZ Treatment Reduces Mucin Content in Differentiated pBECs
pBECs from both donors showed regions of alcian blue/PAS overlap, appearing as a heavy dark 
blue/magenta stain (Figure 4A) (27). It was these alcian blue/PAS overlapping regions that were 
most heavily reduced in non-asthmatic (P = 0.0109) and trending less in asthmatic pBECs (P = 
0.1744) following treatment with DBZ (Figure 4A,B). This was further investigated by performing 
IHC targeting the individual mucin glycoprotein MUC5AC (Figure 4C). Control ALI cultures 
showed distinct labelling of MUC5AC within goblet cells in both non-asthmatics and asthmatics. 
In slight contrast to alcian blue/PAS data MUC5AC staining was significantly (P = 0.008) 
abolished in both asthma and non-asthma groups (Figure 4C,D). 
Inhibition of Notch Signaling Reduces MUC5AC Expression and Secretion
Exposure to DBZ for 96 hours significantly reduced MUC5AC mRNA in cells from non-
asthmatics and asthmatics (Figure 5A). In order to determine whether the reduced production of 
MUC5AC protein within pBECs translated to reduced mucin secretion out of the cell we next 
performed ELISA targeting MUC5AC. At time points up to 72h there was no significant reduction 
in MUC5AC for any concentration of DBZ (Data not shown). Following 96 hours of DBZ 
incubation there was a significant reduction in soluble MUC5AC observed in ALI cultures at all 
concentrations for non-asthma and 10μM for asthma with no concentration-dependent effect 
apparent (Figure 5B). In order to determine whether Notch was influencing regulators of goblet 
cell differentiation and mucin production we quantified expression of the key secretory cell 
regulator SPDEF. SPDEF mRNA was significantly reduced within cells from the same cultures 
as above following DBZ treatment (Figure 5C).
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We washed, fixed, embedded and sectioned cells from each cohort and performed 
immunofluorescent localization targeting MUC5AC to observe differences in secreted mucin 
architecture. MUC5AC glycoprotein adopted a filamentous appearance (Figure 5D; arrow) above 
the apical surface (Figure 5D; dashed line) of pBECs from asthmatics. This mucin was also 
tethered to the apical surface at numerous points. This was in contrast to minimal MUC5AC above 
the apical surface of pBECs from non-asthmatics.
NOTCH3 siRNA treatment significantly reduces MUC5AC production
siRNA-induced knockdown of NOTCH3 was used in conjunction with a previously established 
model in which MUC5AC production could be stimulated and analyzed within monolayer cultures 
(28). A total of 4 independent knockdown experiments were performed. NOTCH1 and NOTCH2 
mRNA was unchanged following Notch3-siRNA treatment whereas as NOTCH3 expression was 
significantly reduced by ~65% (Figure 6A). Full-length NOTCH3- and NICD3 protein levels were 
also significantly reduced following transfection (Figure 6B). Non-transfected and scrambled-
siRNA transfected cells showed observable MUC5AC production when stimulated with 25ng/mL 
EGF for 96 hours using IF and this labelling was lost in Notch3-siRNA treated cells.  Similarly, 
quantification of MUC5AC by in-cell ELISA demonstrated significant increases in media control 
and scrambled-siRNA control cells following 96 hours EGF. The stimulatory effect of EGF on 
MUC5AC was abolished in Notch3-siRNA transfected cells.
Discussion
Mucus production is dysregulated in severe asthma (1, 5, 6). The Notch signaling pathway is a key 
driver of goblet vs ciliated cell differentiation at the epithelium during development as well as in 
response to injury (8-10, 29). Here we have demonstrated that Notch signaling is imbalanced in 
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differentiated airway epithelial cells from donors with asthma. Our study has shown that NOTCH3 
is overexpressed in the airway epithelium of severe asthmatics, whilst NOTCH1 was significantly 
reduced compared to expression in airway epithelium of non-asthmatics. Treatment of ALI 
cultures with the Notch pathway inhibitor DBZ for 96 hours preferentially prevented cleavage of 
NICD3 over NICD1 and resulted in the dramatic loss of the gel-forming mucin MUC5AC. 
Additionally, transfection of immortalized pBECs with Notch3-specific siRNA significantly 
attenuated MUC5AC production. Thus we have provided evidence that Notch3 is a regulator of 
MUC5AC production and its dysregulation may contribute to the increased mucus observed in the 
airways of individuals with asthma.
Various Notch isoforms have been investigated in relation to chronic airway diseases and mucus 
dysregulation with the majority of these studies focusing on Notch1 (8, 30-32) and Notch2 (8, 13). 
Recently, Notch3 has been shown to regulate goblet cell hyperplasia in epithelial cells of the COPD 
airway in response to rhinovirus infection (14). We have shown that Notch3 is significantly 
increased in asthmatic pBECs, both in human lungs and differentiated under ALI culture. 
Currently, data is limited on how Notch3 regulates goblet cell hyperplasia and mucus production 
but our evidence suggests that upregulation of SPDEF may be a consequence of increased Notch3 
signaling. Furthermore, data from this study in addition to data from Jing et al, (2018), suggests 
that Notch3 regulation of mucus production is independent of IL-13 signaling (14). The 
discrepancy observed between Notch1 mRNA (unchanged) and NICD1 protein (reduced) when 
comparing the asthma and non-asthma cohorts is likely due to blunted activation of Notch1 as the 
active NICD1 is primarily detected via western blotting and IHC (Figure1).
Previously, Notch3 has been reported to control the proliferation of airway basal cells through 
Jagged-ligand activation (33). During the establishment of a differentiated epithelium, Notch3 is 
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believed to prime a pool of basal cells into intermediate secretory cells (club cells) that can then 
undergo differentiation into goblet or ciliated phenotypes through downstream Notch1/Notch2-
based signaling (33). In this study, we suggest that Notch3 exhibits an additional role in regulating 
MUC5AC production and secretion within, and adjacent to, goblet cells of the fully differentiated 
airway epithelium as MUC5AC stores are abolished following DBZ-induced Notch3 inhibition. 
Furthermore, this regulation was consistently observed in cells from asthmatics and non-
asthmatics. In lung cancer cells, inhibition of Notch3 has been shown to prevent phosphorylation 
of mitogen-activated protein kinase (MAPK) a core component of the EGFR signaling pathway 
(34). As this pathway has also been implicated in the regulation of MUC5AC in airway epithelial 
cells (9), we speculate that Notch3 is necessary for MUC5AC production in pBECs by facilitating 
the phosphorylation of downstream MAPK. We feel that further studies can answer this 
mechanistic question with more vigor however. 
The failure to observe significant reduction in alcian blue/PAS in pBECs from asthma donors 
compared to non-asthma may indicate that while MUC5AC production is abolished in both cohorts 
following DBZ, mucus production is not completely halted in asthma. We aim to identify which 
of these mucin components persist in pBECs from asthma donors following Notch inhibition in 
future studies.  
DBZ is a potent gamma-secretase inhibitor and therefore should inhibit the cleavage of all Notch 
isoforms equivalently. Nonetheless, we consistently observed that the expression of the NICD3 
domain was significantly reduced following DBZ treatment compared to NICD1. We are unsure 
as to why this reduction, or the reduction of downstream targets, was not concentration-dependent 
but this may be in part due to the differential inhibition of NICD1 and NICD3 cleavage. The 
discrepancy between NICD1 and NICD3 is likely due to non-canonical ligand-independent Notch 
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activation previously described for the Notch1 isoform in human cells (35). This process involves 
ADAM metallopeptidase domain 17 (ADAM17)-stimulated cleavage which is hypothesized to 
preferentially release NICD1 from endosomal compartments independent of gamma-secretase 
activity (35, 36). Alternatively, as the NICD3 domain has a decreased half-life compared to NICD1 
in airway epithelial cells it may not persist following DBZ treatment (37). Indeed, of all Notch 
isoforms only Notch3 has been shown to directly interact with E3-ubiquitin ligase in HEK293T 
cells, resulting in an increase in lysosomal degradation of the protein that can explain its reduced 
persistence (37). To date however, there have been no investigations of the stability of NICDs 
within airway epithelium or how stability may change according to disease status.
Notch3 has a shorter EGF-like domain and an incomplete transactivation domain compared to 
Notch1 and Notch2 (38). These domains regulate NICD activation and transcriptional activity 
explaining the weak transcriptional-activation potential described for NICD3. Indeed, compared 
to NICD1, NICD3 is a poor activator of the canonical Notch target HES1 which controls 
proliferation of stem cells (39, 40). The observation of increased Notch3 and decreased Notch1 in 
lung sections of donors with asthma was very intriguing. We hypothesize that the decrease seen in 
Notch1 protein is a direct result of increased Notch3 in the same cells and is due to Notch3 
competing with Notch1 for binding to Notch cofactors/coactivators such as RBPJ and E2A. 
NICD1 is known to bind to the enhancer region of the Notch1 promoter with the help of such 
cofactors thus self-regulating Notch1 expression (41). Competition for binding to these cofactors 
by Notch3 would then reduce Notch1’s ability to upregulate its own expression.
An alternative pathway of non-canonical Notch signaling, specific to Notch3, is stimulated by the 
Y-box binding protein (YB-1) (26). YB-1 is a cold-shock protein that binds to DNA/RNA and 
regulates DNA reparation, pre-mRNA splicing, mRNA stability and translation. YB-1 has also 
Page 16 of 47
 AJRCMB Articles in Press. Published January 10, 2020 as 10.1165/rcmb.2019-0069OC 
 Copyright © 2020 by the American Thoracic Society 
been shown to activate Notch3 signaling, stimulating γ-secretase cleavage (26). To date no in depth 
investigations have characterized roles of YB-1 in the asthmatic airway, however increased YB-
1/Notch3 signaling is linked with numerous inflammatory diseases such as asthma (26). YB-1 is 
chiefly expressed by immune cells and appears to selectively drive transcription of HES2. As such 
YB-1 is a potential target of future investigations into the role of Notch3 in regulating MUC5AC 
production is the asthmatic airway.
We have identified within human lung sections that NOTCH3 protein appears enriched in regions 
of the epithelium when NOTCH1 is low, and vice versa. Whether competition between NICD1 
and NICD3 exists that activates or represses target genes in the airway epithelium needs further 
investigation. Tsao et al (2009), reported that inhibition of the Notch signaling pathway using 
Rbpjk and Pofut deficient mice as well as the gamma secretase inhibitor DAPT, resulted in the 
significant reduction of Scgb3a2 (secretory cell marker) in lungs during early development (11). 
Subsequent studies by this author (Tsao et al 2011), using post-natal mice showed that conditional 
inactivation of Notch signaling resulted in goblet cell metaplasia and mucin overproduction; thus 
highlighting that Notch-based control of secretory cell differentiation depends on differentiation 
status of the epithelium (32). In contrast, this study has found that the inhibition of Notch signaling 
in differentiated human airway epithelial cells leads to a dramatic reduction of MUC5AC as well 
as SPDEF mRNA. It is possible that the conflicting results between this study and Tsao’s are 
brought about by species specific differences in lung/epithelial morphology between human and 
mouse airways especially during the manipulation of key developmental pathways, or differences 
in the differentiation potential of cells in different studies of different age groups. In support of our 
data, a number of studies have shown that blocking Notch signaling in human airway epithelial 
cells leads to reduced numbers of secretory cells (8, 10).
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A recent study by Singanayagam et al, (2018) has found that fluticasone propionate (FP) treatment 
of a COPD-mouse model, or pBECs from COPD donors, in combination with rhinovirus (RV) 
infection significantly increases MUC5AC production in epithelial cells (42). Notch signaling is 
well known to control the function of glucocorticoid receptor-dependent gene expression (43). As 
Notch3 has also been shown to play a key role in mucus production during RV infection of 
epithelial cells from COPD donors, a process independent of IL-13 (14), Notch3 may therefore be 
a central regulatory protein that controls excess mucus production in airways diseases other than 
asthma.
Here we have shown that pBECs from severe asthmatics exhibit differential expression of Notch3 
compared to non-asthmatics when cultured under identical conditions. Furthermore, MUC5AC 
was found to adopt a filamentous appearance above the apical cell surface and this tethering of 
mucin is analogous to what has been reported in cases of fatal asthma in vivo (44). In the current 
study it was necessary to treat differentiated cells basally so as to maintain cells at ALI for the full 
96 hours. It is unclear how treatment of the basal surface has resulted in such a dramatic reduction 
of MUC5AC within cells at the apical surface, however there are likely two major factors. Firstly, 
DBZ is a small molecule inhibitor that can readily cross the cell plasma membrane and may diffuse 
readily across the small distance and into these apical cells. Secondly, the basolateral surfaces of 
many differentiated cells remain proximal to trans-well membrane pores and therefore would be 
permissive to DBZ diffusion.
siRNA-mediated knockdown of Notch3 results in significantly reduced MUC5AC production. 
Perrais et al (2002) reported that when NCI-H292 lung cancer cells were stimulated with 25µg/mL 
EGF, MUC5AC apomucin becomes detectable by immunolocalization (28). We adopted this 
technique using minimally immortalized pBECs and combined it with immunofluorescent 
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localization as well as in-cell ELISA. This definitively showed that the specific reduction of 
Notch3 prevents the stimulatory effect of EGF on MUC5AC production. Notch1 has been shown 
previously to play a role during EGFR signaling within NCI-H292 cells (9), suggesting that 
MUC5AC production may be under the control of more than one Notch isoform, and potentially 
involves fine alterations in the signaling pathways involved. 
Future investigations using monoclonal antibodies against individual Notch isoforms will allow 
for the specific targeting and inhibition/activation of distinct Notch receptors in differentiated 
epithelial cell culture systems. This study highlights Notch-based regulation of EGF stimulated 
epithelial mucin production and reveals a potentially detrimental role for excess Notch3 in 
asthmatic airway epithelium. Notch3 may be a viable target to alleviate mucin production during 
asthma and other chronic respiratory diseases characterized by chronic overproduction of mucus. 
Author disclosures are available with the text of this article at www.atsjournals.org.
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Table and Figure captions:
TABLE 1: Demographics of asthmatic and non-asthmatic pBEC donors. 
Asthmatic Non-asthmatic
Number, n 11 11
Age, year (SD) 62.2 (12.6) 71.7 (9.1)
Male, n (%) 6 (63.6) 2 (18.2)
ICS, n (%) 11 (100) NA
Daily ICS* dose (BDP† 
equivalent dose), μg (SD) 1509 (575) NA
FEV1‡, % predicted (SD) 54.3 (20.0) 92.8 (16.3)
*ICS = Inhaled corticosteroid 
†BDP = Beclomethasone dipropionate 
‡FEV1; Forced expiratory volume in one second
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FIGURE 1: Notch3 expression is increased in asthma. (A) Quantitative real time (qRT) PCR 
analysis of NOTCH1-3 in differentiated primary bronchial epithelial cells (pBECs) from 
non-asthmatic and asthmatic donors. Data presented as box and whisker plots showing 
median and interquartile range (IQR) representative of 11 independent experiments 
(Mann-Whitney U test).  (B) Western blots comparing Notch intracellular domain 3 
(NICD3) and NICD1 in protein lysates from differentiated pBECs from 5 non-asthmatic 
and 5 asthmatic donors. β-actin (ACTB) staining served as loading control. (C) Western 
blot band densitometry for NICD3 and NICD1 normalized to β-catin . (D) 
Immunohistochemistry (IHC) targeting NOTCH3 or NOTCH1 in human lung tissue from 
asthmatic and non-asthmatic donors. Images representative of a minimum of 4-5 fields of 
view from 6 independent experiments. Scale bar: 20μm. (E) Colour segmentation data for 
NOTCH3 and NOTCH1 IHC comparing asthmatic to non-asthmatic epithelial sections.  
Data presented as box-plots highlighting median stain/μm2/nuclei for all analysed images 
per donor (Mann-Whitney U test). 
FIGURE 2:  NOTCH1 and NOTCH3 are more strongly localized to areas adjacent to MUC5AC 
in differentiated ALI pBECs. NOTCH1 (green) is strongly expressed at areas adjacent to 
MUC5AC (red) expressing cells in ALI pBECs from non-asthmatic donors. NOTCH1 
intensity is relatively lower in cells from donors with asthma. NOTCH3 is more widely 
and strongly localized in ALI pBECs from donors with asthma compared to non-asthma. 
NOTCH3 localization is also present within MUC5AC producing cells but fails to exhibit 
a colocalization signal. Scale 20µm.
FIGURE 3: Dibenzazepine (DBZ) treatment significantly reduced Notch3 at 0.1, 1 and 10μM in 
differentiated primary bronchial epithelial cells (pBECs) from non-asthmatics (Non-As) 
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and asthmatics (As) compared to DMSO (0.02%) vehicle controls ‘D’. (A) Quantitative 
real-time PCR analysis of NOTCH1-3 following DBZ treatment for 96 hours in pBECs 
from asthmatics and non-asthmatics differentiated at air-liquid interface (ALI) for 29 
days. (B) Western blot analysis of NICD3 and NICD1 proteins following DBZ treatment 
for 96 hours in pBECs from both donor cohorts. β-actin (ACTB) staining served as 
loading control. Western blots are representative of a minimum of three independent 
experiments, each experiment conducted under identical conditions on the same day. (C) 
Expression (qPCR) of the Notch3 downstream target HES2, is significantly elevated in 
pBEC ALIs from asthma donors compared to non-asthma. Following DBZ treatment 
HES2 is significantly reduced in both non-asthma and asthma groups. Graphical data 
represent median from five independent experiments ± IQR calculated for each donor 
group (Kruskal-Wallis test).
FIGURE 4: Notch signaling inhibition abolished MUC5AC production in differentiated primary 
bronchial epithelial cells (pBECs) compared to vehicle controls. (A) Alcian blue and 
periodic acid Schiff (PAS) staining analysis of pBECs at air-liquid interface (ALI) from 
asthmatics and non asthmatics treated with DMSO (0.02%) vehicle control or 10μM 
DBZ for 96 hours. Scale bar: 25μm. (B) Colour segmentation based semi-quantification 
of overlapping alcian blue/PAS area (% total epithelial area) following treatment with 
dibezazepine (DBZ) or DMSO vehicle control. (C) IHC staining of mucin MUC5AC 
following treatment with DBZ treatment or DMSO vehicle control for 96 hours. Scale 
bar: 25μm. (D) Colour segmentation based semi-quantification of 3,3'-Diaminobenzidine 
(DAB) labeled MUC5AC area (% total epithelial area) following DBZ treatment. 
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Graphical data represent median from five independent experiments + IQR calculated for 
each donor group (Kruskal Wallis test).
FIGURE 5: Notch signaling inhibition reduced MUC5AC expression and secretion in 
differentiated pBECs compared to DMSO (0.02%) vehicle controls ‘D’. (A) MUC5AC 
mRNA was measured using quantitative real-time (qRT) PCR following DBZ treatment 
at 0.1, 1 and 10μM concentrations, in pBECs at air-liquid interface (ALI) (asthmatic vs 
non-asthmatic). (B) ELISA was used to quantify MUC5AC protein in fluid taken from 
the apical surface of pBECs at ALI  (asthmatic and non-asthmatic). (C) Expression of 
SAM Pointed Domain Containing ETS Transcription Factor (SPDEF) in pBECs at ALI 
treated with 0.1, 1, 10μM DBZ or DMSO vehicle control. (D) IF labeling of MUC5AC 
(red) in differentiated pBECs from asthmatics and non-asthmatics. MUC5AC routinely 
adopted a filamentous tethered appearance (arrow) above the cell surface (dashed line) in 
from asthmatics. Cell nuclei counterstained with DAPI. Graphical data represent median 
from five independent experiments + IQR calculated for each donor group (Kruskal 
Wallils test). Images representative of five independent experiments. Scale bar: 32μm.
FIGURE 6: Specific NOTCH3 small-interfering RNA (siRNA) knockdown significantly 
reduces MUC5AC production in monolayer airway epithelial cells. (A) Quantitative real-
time (qRT) PCR was used to determine levels of NOTCH1-3 mRNAs following siRNA 
knockdown (NOTCH3 vs scrambled control) in BCi-NS1.1 cells. (B) Western blots were 
used to assess knockdown of NOTCH3 full-length and NOTCH3 intracellular domain 
(NICD3) following NOTCH3 or scrambled control siRNA treatment. Western blots are 
representative of three independent experiments, each experiment conducted under 
identical conditions on the same day. (C) MUC5AC IF (red) was analysed in Notch3 
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siRNA-transfected cells compared to scrambled control cells following treatment with 
25ng/mL recombinant human epidermal growth factor (rhEGF). Cell nuclei were 
counterstained with Hoechst 33342 (blue). Fluorescent images are representative of four 
independent experiments. Scale bar: 30μm. (D) MUC5AC expression was quantified 
following transfection with NOTCH3 or scrambled siRNAs using in-cell ELISA (n=4). 
MUC5AC production was determined in the presence of 0.4ng/mL or 25ng/mL rhEGF. 
All graphical data represent average from four independent experiments + SD calculated 
for each group (Kruskal-Wallis test).
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Online Data Supplement:
Blocking Notch3 Signaling Abolishes MUC5AC Production in Airway Epithelial Cells from 
Asthmatics 
Andrew T Reid, Kristy S Nichol, Punnam Chander-Veerati, Fatemeh Moheimani, Anthony Kicic, 
Stephen M Stick, Nathan W Bartlett, Chris L Grainge, Peter A B Wark, Philip M Hansbro, Darryl 
A Knight
Additional Materials and Methods: 
pBEC Cell Culture and Pharmacological Inhibition: Prior to culture at the ALI, pBECs were 
seeded at a density of 1.8 x 105 cells/cm2 onto transwell polymer inserts (transparent, 0.4μm 
pore; Corning, NY, USA) at passage two. Cells were grown in low-glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma-Aldrich, MO, USA) and an equivalent volume bronchial 
epithelial cell basal medium (BEBM; Lonza)  containing; hydrocortisone (Lonza; CC-4031F), 
insulin (bovine) (Lonza; CC-4021F), Epinephrine (Lonza; CC-4221F), bovine pituitary extract 
(Lonza; CC-4009F), transferrin (Lonza; CC4205F), ethanolamine (80µM final), MgCl2 (0.3mM 
final), MgSO4 (0.4mM final), bovine serum albumin (0.5mg/mL), penicillin-streptomycin 
(100U/mL-100µg/mL final) and Amphotericin B (2.5µg/mL final). This 50:50 medium was 
supplemented with, all-trans retinoic acid (30ng/mL; Sigma-Aldrich) and recombinant human 
epidermal growth factor (rhEGF, 10ng/mL; Bioscientific, NSW, Australia). Cells were lifted to 
the ALI when confluent, apical medium was removed and basolateral medium was replaced with 
50:50 media (30ng/mL retinoic acid, 0.4ng/mL rhEGF). Basolateral medium was changed every 
2-3 days. Trans-epithelial electrical resistance (TEER) measurements were made using an 
epithelial voltohmmeter (EVOM2; WPI, FL, USA) and apical surface washes were performed 
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every week using 500µL 37°C Dulbecco’s phosphate buffered saline (DPBS; GE Healthcare, 
Little Chalfont, UK).
Dibenzazepine Treatment: Basolateral medium was replaced with 50/50 medium (30ng/mL 
retinoic acid, 25ng/mL rhEGF) containing 0.1, 1, 10µM DBZ or vehicle control (0.02% v/v 
DMSO; Sigma). Apical surface fluid was aspirated every 24 hours, while basolateral medium 
was aspirated and replaced at 48 hours. All apical and basolateral fluid was stored at -80°C. At 
96 hours cell were harvested for RNA, protein or fixed in 10% Formalin (Lomb Scientific, NSW, 
Australia) for histology.
BCI-Ns1.1 Cell Culture and siRNA Transfection: Transfection complexes containing 
predesigned Silencer select Notch3 siRNA (s9640; Thermo Fisher Scientific, MA, USA), 
Silencer Select negative control siRNA (4390843; Thermo Fisher Scientific), or media control 
were prepared using siPORT NeoFX (Thermo Fisher Scientific) transfection agent according to 
manufacturer’s instructions. Briefly, suspensions of BCI-NS1.1 cells (n=4) were incubated in a 
mixture of siPORT NeoFX transfection agent (Thermo Fisher Scientific) and 50 nmol/L siRNA 
oligonucleotides in Opti-MEM I (Thermo Fisher Scientific).
Human lung tissue Immunohistochemistry (IHC) and colorimetry: Sections were subjected to 
immunohistochemical staining and all steps were conducted simultaneously. Briefly, sections were 
deparaffinised in xylene followed by rehydration through decreasing ethanol concentrations. 
Following antigen retrieval and peroxidase quenching, slides were blocked in Tris-buffered saline 
(pH 7.4) containing 0.05% v/v Tween-20 (Sigma-Aldrich) (TBS-T) 1% w/v Casein (Thermo 
Fisher Scientific). Slides were incubated overnight at 4°C with rabbit polyclonal anti-Notch3 
(4µg/mL) (ab23426; Abcam, Cambridge, UK), rabbit polyclonal anti-Notch1 (4µg/mL) (ab27526; 
Page 39 of 47
 AJRCMB Articles in Press. Published January 10, 2020 as 10.1165/rcmb.2019-0069OC 
 Copyright © 2020 by the American Thoracic Society 
Abcam) in Tris-buffered saline (pH 7.4) containing 0.05% v/v Tween-20 (Sigma-Aldrich) (TBS-
T). Goat anti-rabbit secondary conjugated to horseradish peroxidase (2µg/mL) (ab6721; Abcam) 
was incubated for 1 hour at room temperature prior to 3,3’-diaminobenzidine tetrahydrochloride 
(DAB+) chromogen development (Agilent Technologies, CA, USA). Sections were 
counterstained with Mayer’s hematoxylin (Agilent Technologies). Rabbit IgG isotype control 
antibody (ab125938) was used as negative control. Sections were mounted and photographed using 
a phase contrast microscope (Eclipse E400; Nikon, Tokyo, Japan) with attached high resolution 
camera (Digital Sight DS-5m, Nikon). A minimum of 5 images were taken of small and medium 
sized airways per section (between 1 and 5mm inner diameter) with identical white balancing, 
contrast ring position and exposure times. Measurements of airway epithelial cell area were made 
using open-source imageJ software (ImageJ/NIH, MD, USA) and all non-epithelial cell areas were 
removed from subsequent analysis. Epithelial regions were subjected to colour deconvolution as 
previously described (E1). Total DAB+ (brown) positive area of each epithelial image was 
recorded and divided by the total area of the respective epithelium. So as to account for obliquely 
cut sections with more cell layers, this value was divided by the total number of nuclei which were 
counted manually. Mean stain/µm2/nuclei values were normalized to 1 for non-asthmatic samples 
for each antibody. Non-parametric Kruskal-Wallis test was used to determine statistical 
significance.
Air-liquid interface protein extraction and western blotting: Following endpoints for each ALI 
culture, trans-well membranes/ cells were washed briefly with PBS, cut in half, and placed in ice-
cold lysis buffer (50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA, 1% triton X-100, 0.1% 
sodium dodecyl sulfate, 0.5% sodium deoxycholate) containing protease inhibitor cocktail (Roche, 
Basel, Switzerland) for 30min. Following incubation trans-well membranes were removed and 
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cellular protein samples were aspirated following centrifugation. Samples were electrophoresed 
on 7.5% polyacrylamide gels (Bio-Rad, CA, USA) after which protein was transferred onto 
Immobilon polyvinylidene difluoride (PVDF) (Merck Millipore, MA, USA) or Amersham Protran 
nitrocellulose (GE Healthcare) membranes. Membranes were blocked and subsequently incubated 
with primary antibodies; anti-NOTCH3 (0.2μg/mL), anti-NOTCH1 (0.2μg/mL), or anti-βactin 
(ab8227; Abcam) (0.05μg/mL). Membranes were incubated with goat anti-rabbit (ab6721; 
Abcam) or rabbit anti-mouse (ab6728; Abcam) secondary antibodies conjugated to horseradish 
peroxidase (HRP). Protein bands were visualized using SuperSignal West Femto (Thermo Fisher 
Scientific) chemiluminescence (ChemiDoc MP, Bio-Rad).
IHC, immunofluorescence (IF) and alcian blue/PAS staining in ALI cultures: ALI 
membranes were coated apically with 2% w/v low melting point agarose to protect cells. 
Samples were subjected to standard histological ethanol/ xylene dehydration followed by 
paraffin embedding. IHC was performed on 5μm thick sections of membrane/cells as previously 
detailed for human airway sections, except mouse monoclonal anti-MUC5AC (ab3649; Abcam) 
primary antibody was used at 2μg/mL. For IF, ALI sections were exposed to direct white light 
for >24 hours to quench any endogenous fluorescence. Samples were deparaffinised, rehydrated 
and subjected to antigen retrieval as above. Samples were blocked with 10% v/v goat serum and 
3% bovine serum albumin (BSA) (GE Healthcare) in TBS-T, followed by overnight incubation 
in anti-NOTCH3, anti-NOTCH1 in combination with anti-MUC5AC. Alexa-fluor 488- 
conjugated donkey anti-rabbit (A-21203: Invitrogen, CA, USA) or 594-conjugated donkey anti-
mouse secondary antibody (A-21203; Invitrogen) and mounting media with DAPI (ProLong 
Gold; Thermo Fisher Scientific) were used for fluorescent visualization of NOTCH, MUC5AC 
and nuclei respectively. Images were obtained using an Axio Imager M2 automated fluorescence 
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microscope (Carl Zeiss AG, Oberkochen, Germany) with identical capture settings/processing 
for all images. Standard Alcian blue pH2.5 and Periodic Acid Schiff (PAS) staining (AB/PAS) 
was performed on ALI sections to observe total mucin content. For IHC and AB/PAS, a 
minimum of 5 images were taken randomly across sections of each ALI membrane and mean 
value recorded. This was repeated for 5 donor replicates with identical white balancing, contrast 
ring position and exposure times (E2). Measurements of airway epithelial cell area were made 
using open-source imageJ software (ImageJ/NIH, MD, USA) and all non-epithelial cell areas 
were removed from subsequent analysis. Epithelial regions were subjected to identical colour 
deconvolution and thresholding for DAB or AB/PAS overlap to obtain distinct areas with 
positive stain. The positive stain area of each epithelial image was recorded and divided by the 
total area of the respective epithelium and expressed as a percentage (% total area). Mann-
Whitney U test was used to determine statistical significance.
Real-time quantitative RT-qPCR: Total RNA was extracted from cells using the RNeasy kit 
(Qiagen, Hilden, Germany) and cDNA was prepared as previously described on a T100 Thermal 
Cycler (Bio-Rad) (E3). Quantitative PCR (qPCR) was performed on a Mastercycler Realplex2 
(Eppendorf AG, Hamburg, Germany) using Taqman gene expression mastermix (Thermo Fisher 
Scientific). Target mRNA expression was normalized to 18S ribosomal RNA (18S rRNA) 
(4318839; Thermo Fisher Scientific) as previously described (E4). Taqman® Gene Expression 
Assay primers (4331182; Thermo Fisher Scientific) were utilized targeting NOTCH1 
(Hs01062014_m1), NOTCH2 (Hs01050702_m1), NOTCH3 (Hs01128537_m1), NOTCH4 
(Hs00965889_m1), SPDEF (Hs00171942_m1), HES2 (Hs01021800_g1) and MUC5AC 
(Hs00873651_m1) for qPCR reactions. All qPCR results are presented as mean log2 fold change 
relative to control with statistics performed on ΔΔCt from independent biological replicates (E5).
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MUC5AC ELISA: As purified standards of MUC5AC are commercially unavailable, MUC5AC-
rich protein was obtained from cultures of Calu-3 human lung adenocarcinoma epithelial cells 
grown to ALI (E6). Serial dilutions were made of Calu-3 apical surface fluid and linear MUC5AC 
standard curve was confirmed (data not shown). Mucin-containing ALI apical surface fluid was 
incubated with 500μL warm PBS and lightly agitated before aspiration. Apical washes were 
collected every 24 hours and data is presented as the relative amount of MUC5AC secreted across 
sequential 24 hour time-windows (i.e. 0-24, 24-48, 48-72, and 72-96h). Aspirates and standards 
were agitated at 1000rpm at 42°C to homogenize consistency, coated into multi-well plates 
(Thermo Fisher Scientific) and dried overnight in 37°C oven (Benchmark Scientific, NJ, USA). 
After washing, plates were blocked (5% w/v BSA in PBS) and incubated with biotinylated mouse 
monoclonal anti-MUC5AC (ab79082; Abcam) (0.2μg/mL) for 1 hour. Plates were incubated with 
Streptavidin-HRP conjugate (Thermo-Fisher Scientific) and developed using 3,3',5,5'-
tetramethylbenzidine (TMB; Thermo-Fisher Scientific).
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Supplementary Figures
Figure E1: Notch2 intracellular domain (NICD2) protein in ALI pBECs differentiated to day25 and 
immunoblotted.
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Figure E2: Cell viability of ALI pBECs treated with 10µM DBZ for 96 hours. Cells were trypsinized and 
assessed via 0.4% trypan blue exclusion.
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Figure E3: Cell types of differentiated ALI pBECs (Day29) do not change following treatment with 
10µM DBZ. (A) Western blots targeting specific markers of goblet cells (chloride channel accessory 1 
protein: CLCA1) and ciliated cells (acetylated β-tubulin: Ac. Β-Tub). (B) Densitometry for CLCA1 and 
Ac. Β-Tub normalized to β-actin (ACTB).
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